Stereotactic Breast Biopsy: Comparison of Histologic Underestimation Rates with 11- and 9-Gauge Vacuum-Assisted Breast Biopsy

Abstract

There was no statistically significant difference between 11-gauge biopsy and 9-gauge biopsy in underestimation of atypical ductal hyperplasia and ductal carcinoma in situ.

Mammotome® and EnCor®: comparison of two systems for stereotactic vacuum-assisted core biopsy in the characterisation of suspicious mammographic microcalcifications alone

“…The two systems used in this study differ in the size of the probe needle, with the EnCor ® using the larger (10G) needle compared to the Mammotome ® (11G). This difference in size, a single value in the Gauge scale, did not lead to superior performance as also observed by Lourenco et al [11]. Significantly better performances were observed when greater calibre differences were considered, as in the study by Venkataraman et al [12], who compared 8G vs. 11G needles.…”

Predictive factors for invasive cancer in surgical specimens following an initial diagnosis of ductal carcinoma in situ after stereotactic vacuum-assisted breast biopsy in microcalcification-only lesions

“…Although SVAB allows more accurate histopathologic results, underestimation still occurs (7,10,18). Some investigators have found rates of underestimation ranging from 5% to 29% for DCIS at SVAB (6,9,(11)(12)(13). In this study, the underestimation rate of DCIS was 18%.…”

“…Underestimation of DCIS lesions occurs when an invasive component is found after surgery, which had been missed at the initial preoperative sampling. The underestimation rate of stereotactic 14-gauge automated core biopsy in DCIS was reported as 16%-35% (9-11), while that of SVAB was 5%-29% (6,9,(11)(12)(13).…”

Factors that impact the upgrading of atypical ductal hyperplasia

“…Technical advances in percutaneous core needle biopsy, such as increasing needle diameter from 14-gauge to 11-gauge and adding a vacuum device, have allowed larger samples of tissue to be obtained (5,6), substantially improving the accuracy of diagnosis. Despite these improvements, the rate of underestimation for ADH has been reported as 10% to 26% for 11-gauge vacuum-assisted biopsy (VAB) (2,14,(21)(22)(23)(24)(25)(26)(27)(28). In this study, 11-gauge SVAB was associated with a lower rate of underestimation for ADH (20.6%), compared to USguided 14-gauge automated biopsy (41.7%) (P = 0.007).…”